Title: Combined use of CDAI and blood indices for assessing endoscopic activity in ileocolic
Crohn’s disease
Version: 2 Date: 03 Aug 2023
Reviewer:  Bhaskar Kante
Reviewer's report:
Dear Author,  I am glad to read the reply for the comments point by point. The manuscript is
well modified with comments made by reviewers in a constructive manner. Here are my few
comments
1. The inclusion of CALM  trial in introduction in the section of CDAI. Please reframe the
paragraph as it doesn’t convey the message clearly
2. As mentioned in table 1 about medications
Immunosupressants can we assume it as azathiopurine and methotrexate
which can frequently cause cytopenia
Can we negate the medication affect on assessment of PLr and its correlation with endoscopic
activity?
3.   Line no 72 change structuring to stricturing
Title: Combined use of CDAI and blood indices for assessing endoscopic activity in ileocolic
Crohn’s disease
Version: 2 Date: 03 Aug 2023
Reviewer:  Bhaskar Kante
Reviewer's report:
Dear Author,  I am glad to read the reply for the comments point by point. The manuscript is
well modified with comments made by reviewers in a constructive manner. Here are my few
comments
1. The inclusion of CALM  trial in introduction in the section of CDAI. Please reframe the
paragraph as it doesn’t convey the message clearly
2. As mentioned in table 1 about medications
Immunosupressants can we assume it as azathiopurine and methotrexate
which can frequently cause cytopenia
Can we negate the medication affect on assessment of PLr and its correlation with endoscopic
activity?
3.   Line no 72 change structuring to stricturing
Please review this paper.
user
Title: Combined use of CDAI and blood indices for assessing endoscopic activity in ileocolic
Crohn’s disease
Version: 2 Date: 03 Aug 2023
Reviewer:  Bhaskar Kante
Reviewer's report:
Dear Author,  I am glad to read the reply for the comments point by point. The manuscript is
well modified with comments made by reviewers in a constructive manner. Here are my few
comments
1. The inclusion of CALM  trial in introduction in the section of CDAI. Please reframe the
paragraph as it doesn’t convey the message clearly
2. As mentioned in table 1 about medications
Immunosupressants can we assume it as azathiopurine and methotrexate
which can frequently cause cytopenia
Can we negate the medication affect on assessment of PLr and its correlation with endoscopic
activity?
3.   Line no 72 change structuring to stricturing
assistant